New Science Ventures

New Science Ventures, LLC (NSV) is a venture capital firm founded in 2004, based in Greenwich, Connecticut, with an additional office in London. It invests in early and late-stage companies taking novel scientific approaches to address significant unmet needs in life sciences and information technology. The firm brings deep investment experience and board-level expertise across both sectors in the US and Europe, partnering with founders from early development through key value inflection points, with a global footprint spanning the US, Europe, India, and China. NSV focuses on sectors with strong, decades-long tailwinds, including biotech, advanced materials, and deep tech. Notable investments include Paragraf, PlanetiQ, Antevia Networks, Glydways, Resolve Therapeutics, Novadip, NorthSea Therapeutics, biomodal, Phase Four, and BrightVolt. The firm seeks differentiated opportunities with strong intellectual property and substantial market potential, having led rounds such as Phase Four's $26 million Series B. Its criteria favor scientifically defensible innovation across biotech and information technology with clear paths to significant market impact